Biomerica Inc BMRA
We take great care to ensure that the data presented and summarized in this overview for BIOMERICA INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding BMRA
View all-
Granahan Investment Management, LLC Waltham, MA527KShares$210,9840.01% of portfolio
-
Russell Investments Group, Ltd.225KShares$90,1740.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA169KShares$67,6040.0% of portfolio
-
Potomac Capital Management, Inc.168KShares$67,0800.37% of portfolio
-
Black Rock Inc. New York, NY149KShares$59,6320.0% of portfolio
-
Geode Capital Management, LLC Boston, MA124KShares$49,7450.0% of portfolio
-
Ubs Group Ag91.7KShares$36,6760.0% of portfolio
-
Virtu Financial LLC New York, NY63KShares$25,2180.0% of portfolio
-
Fore Capital, LLC59.7KShares$23,8720.01% of portfolio
-
State Street Corp Boston, MA37.2KShares$14,8920.0% of portfolio
Latest Institutional Activity in BMRA
Top Purchases
Top Sells
About BMRA
Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome therapy technology and diagnostic-guided therapy; Helicobacter pylori products, as well as develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
Insider Transactions at BMRA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 13
2024
|
Catherine Coste Director |
BUY
Grant, award, or other acquisition
|
Direct |
85,000
+39.76%
|
$0
$0.31 P/Share
|
|
Dec 13
2024
|
Lu Gary Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
155,000
+50.0%
|
$0
$0.31 P/Share
|
|
Dec 13
2024
|
Allen Barbieri Executive Vice Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
110,000
+36.87%
|
$0
$0.31 P/Share
|
|
Dec 13
2024
|
David Moatazedi Director |
BUY
Grant, award, or other acquisition
|
Direct |
85,000
+50.0%
|
$0
$0.31 P/Share
|
|
Dec 13
2024
|
Zackary S. Irani Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
250,000
+16.44%
|
$0
$0.31 P/Share
|
|
Dec 13
2024
|
Jane Emerson Director |
BUY
Grant, award, or other acquisition
|
Direct |
85,000
+35.27%
|
$0
$0.31 P/Share
|
|
May 25
2023
|
Zackary S. Irani Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
200
+0.02%
|
$200
$1.55 P/Share
|
|
May 24
2023
|
Zackary S. Irani Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
500
+0.05%
|
$500
$1.61 P/Share
|
|
May 12
2023
|
Zackary S. Irani Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
1,700
+0.17%
|
$1,700
$1.17 P/Share
|
|
May 10
2023
|
Zackary S. Irani Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
500
+0.05%
|
$500
$1.27 P/Share
|
|
May 09
2023
|
Zackary S. Irani Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
300
+0.03%
|
$300
$1.39 P/Share
|
|
May 04
2023
|
Zackary S. Irani Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
1,000
+0.1%
|
$1,000
$1.36 P/Share
|
|
Apr 28
2023
|
Zackary S. Irani Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
1,800
+0.18%
|
$1,800
$1.34 P/Share
|
|
Apr 27
2023
|
Zackary S. Irani Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
2,600
+0.25%
|
$2,600
$1.31 P/Share
|
|
Apr 26
2023
|
Zackary S. Irani Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
7,000
+0.69%
|
$7,000
$1.26 P/Share
|
|
Jan 27
2023
|
Allen Barbieri Executive Vice Chairman |
BUY
Open market or private purchase
|
Direct |
1,538
+1.5%
|
$3,076
$2.94 P/Share
|
|
Jan 26
2023
|
Catherine Coste Director |
BUY
Open market or private purchase
|
Direct |
2,190
+4.76%
|
$4,380
$2.96 P/Share
|
|
Jan 25
2023
|
Zackary S. Irani Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
1,800
+0.18%
|
$3,600
$2.85 P/Share
|
|
Jan 24
2023
|
Zackary S. Irani Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
2,000
+0.2%
|
$4,000
$2.81 P/Share
|
|
Oct 26
2020
|
Catherine Coste Director |
BUY
Open market or private purchase
|
Indirect |
9,100
+50.0%
|
$45,500
$5.45 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 770K shares |
|---|